{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&max-ddpModified.=2019-09-05T10%3A15%3A15.353Z&min-date=2019-07-18&ddpModified.=2019-09-02T17%3A35%3A21.682Z&hansardHeading=Medical+Treatments", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&max-ddpModified.=2019-09-05T10%3A15%3A15.353Z&min-date=2019-07-18&ddpModified.=2019-09-02T17%3A35%3A21.682Z&hansardHeading=Medical+Treatments", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&max-ddpModified.=2019-09-05T10%3A15%3A15.353Z&min-date=2019-07-18&ddpModified.=2019-09-02T17%3A35%3A21.682Z&_metadata=all&hansardHeading=Medical+Treatments", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&_page=0&max-ddpModified.=2019-09-05T10%3A15%3A15.353Z&min-date=2019-07-18&ddpModified.=2019-09-02T17%3A35%3A21.682Z&hansardHeading=Medical+Treatments", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&max-ddpModified.=2019-09-05T10%3A15%3A15.353Z&min-date=2019-07-18&ddpModified.=2019-09-02T17%3A35%3A21.682Z&hansardHeading=Medical+Treatments", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2019-05-24&max-ddpModified.=2019-09-05T10%3A15%3A15.353Z&min-date=2019-07-18&ddpModified.=2019-09-02T17%3A35%3A21.682Z&hansardHeading=Medical+Treatments", "items" : [{"_about" : "http://data.parliament.uk/resources/1142693", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1142693/answer", "answerText" : {"_value" : "
Further to the answer the Minister of State for Care (Caroline Dinenage MP) gave on 2 April 2019 to Question 236381, that NHS England has considered this issue, and does not believe that a gap has been created as a result of the closure of Commissioning Support Programme for treatments that are awaiting review by the Clinical Priorities Advisory Group.<\/p>
The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme.<\/p>
All policy propositions relating to topics previously being supported in development through the Commissioning Support Programme have been handed over at the agreed stage for post stakeholder testing. These are now being progressed though the usual development process. Further information is available at the following link:<\/p>